

Granulomatosis with Polyangiitis Drug Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/GC04C791AFE0EN.html>

Date: March 2022

Pages: 78

Price: US\$ 3,250.00 (Single User License)

ID: GC04C791AFE0EN

Abstracts

This report contains market size and forecasts of Granulomatosis with Polyangiitis Drug in global, including the following market information:

Global Granulomatosis with Polyangiitis Drug Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Granulomatosis with Polyangiitis Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)

Global top five Granulomatosis with Polyangiitis Drug companies in 2021 (%)

The global Granulomatosis with Polyangiitis Drug market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Benralizumab Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Granulomatosis with Polyangiitis Drug include Bionovis SA, Bristol-Myers Squibb Company, ChemoCentryx Inc, Coherus BioSciences Inc, Genor BioPharma Co Ltd, GlaxoSmithKline Plc, Iltoo Pharma, Panacea Biotec Ltd and Sandoz International GmbH and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Granulomatosis with Polyangiitis Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Granulomatosis with Polyangiitis Drug Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Granulomatosis with Polyangiitis Drug Market Segment Percentages, by Type, 2021 (%)

Benralizumab

Avacopan

Rituximab Biosimilar

Others

Global Granulomatosis with Polyangiitis Drug Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Granulomatosis with Polyangiitis Drug Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Granulomatosis with Polyangiitis Drug Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Granulomatosis with Polyangiitis Drug Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Granulomatosis with Polyangiitis Drug revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies Granulomatosis with Polyangiitis Drug revenues share in global market, 2021 (%)

Key companies Granulomatosis with Polyangiitis Drug sales in global market, 2017-2022 (Estimated), (K Pcs)

Key companies Granulomatosis with Polyangiitis Drug sales share in global market,

2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bionovis SA

Bristol-Myers Squibb Company

ChemoCentryx Inc

Coherus BioSciences Inc

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

Iltoo Pharma

Panacea Biotec Ltd

Sandoz International GmbH

The International Biotechnology Center (IBC) Generium

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Granulomatosis with Polyangiitis Drug Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Granulomatosis with Polyangiitis Drug Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL GRANULOMATOSIS WITH POLYANGIITIS DRUG OVERALL MARKET SIZE

- 2.1 Global Granulomatosis with Polyangiitis Drug Market Size: 2021 VS 2028
- 2.2 Global Granulomatosis with Polyangiitis Drug Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Granulomatosis with Polyangiitis Drug Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Granulomatosis with Polyangiitis Drug Players in Global Market
- 3.2 Top Global Granulomatosis with Polyangiitis Drug Companies Ranked by Revenue
- 3.3 Global Granulomatosis with Polyangiitis Drug Revenue by Companies
- 3.4 Global Granulomatosis with Polyangiitis Drug Sales by Companies
- 3.5 Global Granulomatosis with Polyangiitis Drug Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Granulomatosis with Polyangiitis Drug Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Granulomatosis with Polyangiitis Drug Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Granulomatosis with Polyangiitis Drug Players in Global Market
 - 3.8.1 List of Global Tier 1 Granulomatosis with Polyangiitis Drug Companies
 - 3.8.2 List of Global Tier 2 and Tier 3 Granulomatosis with Polyangiitis Drug Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Global Granulomatosis with Polyangiitis Drug Market Size Markets, 2021 & 2028

4.1.2 Benralizumab

4.1.3 Avacopan

4.1.4 Rituximab Biosimilar

4.1.5 Others

4.2 By Type - Global Granulomatosis with Polyangiitis Drug Revenue & Forecasts

4.2.1 By Type - Global Granulomatosis with Polyangiitis Drug Revenue, 2017-2022

4.2.2 By Type - Global Granulomatosis with Polyangiitis Drug Revenue, 2023-2028

4.2.3 By Type - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

4.3 By Type - Global Granulomatosis with Polyangiitis Drug Sales & Forecasts

4.3.1 By Type - Global Granulomatosis with Polyangiitis Drug Sales, 2017-2022

4.3.2 By Type - Global Granulomatosis with Polyangiitis Drug Sales, 2023-2028

4.3.3 By Type - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

4.4 By Type - Global Granulomatosis with Polyangiitis Drug Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Granulomatosis with Polyangiitis Drug Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Granulomatosis with Polyangiitis Drug Revenue & Forecasts

5.2.1 By Application - Global Granulomatosis with Polyangiitis Drug Revenue, 2017-2022

5.2.2 By Application - Global Granulomatosis with Polyangiitis Drug Revenue, 2023-2028

5.2.3 By Application - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

5.3 By Application - Global Granulomatosis with Polyangiitis Drug Sales & Forecasts

5.3.1 By Application - Global Granulomatosis with Polyangiitis Drug Sales, 2017-2022

- 5.3.2 By Application - Global Granulomatosis with Polyangiitis Drug Sales, 2023-2028
- 5.3.3 By Application - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028
- 5.4 By Application - Global Granulomatosis with Polyangiitis Drug Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

- 6.1 By Region - Global Granulomatosis with Polyangiitis Drug Market Size, 2021 & 2028
- 6.2 By Region - Global Granulomatosis with Polyangiitis Drug Revenue & Forecasts
 - 6.2.1 By Region - Global Granulomatosis with Polyangiitis Drug Revenue, 2017-2022
 - 6.2.2 By Region - Global Granulomatosis with Polyangiitis Drug Revenue, 2023-2028
 - 6.2.3 By Region - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028
- 6.3 By Region - Global Granulomatosis with Polyangiitis Drug Sales & Forecasts
 - 6.3.1 By Region - Global Granulomatosis with Polyangiitis Drug Sales, 2017-2022
 - 6.3.2 By Region - Global Granulomatosis with Polyangiitis Drug Sales, 2023-2028
 - 6.3.3 By Region - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028
- 6.4 North America
 - 6.4.1 By Country - North America Granulomatosis with Polyangiitis Drug Revenue, 2017-2028
 - 6.4.2 By Country - North America Granulomatosis with Polyangiitis Drug Sales, 2017-2028
 - 6.4.3 US Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
 - 6.4.4 Canada Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
 - 6.4.5 Mexico Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
- 6.5 Europe
 - 6.5.1 By Country - Europe Granulomatosis with Polyangiitis Drug Revenue, 2017-2028
 - 6.5.2 By Country - Europe Granulomatosis with Polyangiitis Drug Sales, 2017-2028
 - 6.5.3 Germany Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
 - 6.5.4 France Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
 - 6.5.5 U.K. Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
 - 6.5.6 Italy Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
 - 6.5.7 Russia Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
 - 6.5.8 Nordic Countries Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
 - 6.5.9 Benelux Granulomatosis with Polyangiitis Drug Market Size, 2017-2028
- 6.6 Asia
 - 6.6.1 By Region - Asia Granulomatosis with Polyangiitis Drug Revenue, 2017-2028

6.6.2 By Region - Asia Granulomatosis with Polyangiitis Drug Sales, 2017-2028

6.6.3 China Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.6.4 Japan Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.6.5 South Korea Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.6.6 Southeast Asia Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.6.7 India Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.7 South America

6.7.1 By Country - South America Granulomatosis with Polyangiitis Drug Revenue, 2017-2028

6.7.2 By Country - South America Granulomatosis with Polyangiitis Drug Sales, 2017-2028

6.7.3 Brazil Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.7.4 Argentina Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Sales, 2017-2028

6.8.3 Turkey Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.8.4 Israel Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.8.5 Saudi Arabia Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

6.8.6 UAE Granulomatosis with Polyangiitis Drug Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 Bionovis SA

7.1.1 Bionovis SA Corporate Summary

7.1.2 Bionovis SA Business Overview

7.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Major Product Offerings

7.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)

7.1.5 Bionovis SA Key News

7.2 Bristol-Myers Squibb Company

7.2.1 Bristol-Myers Squibb Company Corporate Summary

7.2.2 Bristol-Myers Squibb Company Business Overview

7.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Major Product Offerings

7.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)

- 7.2.5 Bristol-Myers Squibb Company Key News
- 7.3 ChemoCentryx Inc
 - 7.3.1 ChemoCentryx Inc Corporate Summary
 - 7.3.2 ChemoCentryx Inc Business Overview
 - 7.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Major Product Offerings
 - 7.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)
 - 7.3.5 ChemoCentryx Inc Key News
- 7.4 Coherus BioSciences Inc
 - 7.4.1 Coherus BioSciences Inc Corporate Summary
 - 7.4.2 Coherus BioSciences Inc Business Overview
 - 7.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Major Product Offerings
 - 7.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)
 - 7.4.5 Coherus BioSciences Inc Key News
- 7.5 Genor BioPharma Co Ltd
 - 7.5.1 Genor BioPharma Co Ltd Corporate Summary
 - 7.5.2 Genor BioPharma Co Ltd Business Overview
 - 7.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Major Product Offerings
 - 7.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)
 - 7.5.5 Genor BioPharma Co Ltd Key News
- 7.6 GlaxoSmithKline Plc
 - 7.6.1 GlaxoSmithKline Plc Corporate Summary
 - 7.6.2 GlaxoSmithKline Plc Business Overview
 - 7.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Major Product Offerings
 - 7.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)
 - 7.6.5 GlaxoSmithKline Plc Key News
- 7.7 Iltoo Pharma
 - 7.7.1 Iltoo Pharma Corporate Summary
 - 7.7.2 Iltoo Pharma Business Overview
 - 7.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Major Product Offerings
 - 7.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)

7.7.5 Iltoo Pharma Key News

7.8 Panacea Biotec Ltd

7.8.1 Panacea Biotec Ltd Corporate Summary

7.8.2 Panacea Biotec Ltd Business Overview

7.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Major Product

Offerings

7.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)

7.8.5 Panacea Biotec Ltd Key News

7.9 Sandoz International GmbH

7.9.1 Sandoz International GmbH Corporate Summary

7.9.2 Sandoz International GmbH Business Overview

7.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Major Product Offerings

7.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)

7.9.5 Sandoz International GmbH Key News

7.10 The International Biotechnology Center (IBC) Generium

7.10.1 The International Biotechnology Center (IBC) Generium Corporate Summary

7.10.2 The International Biotechnology Center (IBC) Generium Business Overview

7.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Major Product Offerings

7.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2017-2022)

7.10.5 The International Biotechnology Center (IBC) Generium Key News

8 GLOBAL GRANULOMATOSIS WITH POLYANGIITIS DRUG PRODUCTION CAPACITY, ANALYSIS

8.1 Global Granulomatosis with Polyangiitis Drug Production Capacity, 2017-2028

8.2 Granulomatosis with Polyangiitis Drug Production Capacity of Key Manufacturers in Global Market

8.3 Global Granulomatosis with Polyangiitis Drug Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

10 GRANULOMATOSIS WITH POLYANGIITIS DRUG SUPPLY CHAIN ANALYSIS

- 10.1 Granulomatosis with Polyangiitis Drug Industry Value Chain
- 10.2 Granulomatosis with Polyangiitis Drug Upstream Market
- 10.3 Granulomatosis with Polyangiitis Drug Downstream and Clients
- 10.4 Marketing Channels Analysis
 - 10.4.1 Marketing Channels
 - 10.4.2 Granulomatosis with Polyangiitis Drug Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

- 12.1 Note
- 12.2 Examples of Clients
- 12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Granulomatosis with Polyangiitis Drug in Global Market

Table 2. Top Granulomatosis with Polyangiitis Drug Players in Global Market, Ranking by Revenue (2021)

Table 3. Global Granulomatosis with Polyangiitis Drug Revenue by Companies, (US\$, Mn), 2017-2022

Table 4. Global Granulomatosis with Polyangiitis Drug Revenue Share by Companies, 2017-2022

Table 5. Global Granulomatosis with Polyangiitis Drug Sales by Companies, (K Pcs), 2017-2022

Table 6. Global Granulomatosis with Polyangiitis Drug Sales Share by Companies, 2017-2022

Table 7. Key Manufacturers Granulomatosis with Polyangiitis Drug Price (2017-2022) & (USD/Pcs)

Table 8. Global Manufacturers Granulomatosis with Polyangiitis Drug Product Type

Table 9. List of Global Tier 1 Granulomatosis with Polyangiitis Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Granulomatosis with Polyangiitis Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Global Granulomatosis with Polyangiitis Drug Revenue (US\$, Mn), 2017-2022

Table 13. By Type - Global Granulomatosis with Polyangiitis Drug Revenue (US\$, Mn), 2023-2028

Table 14. By Type - Global Granulomatosis with Polyangiitis Drug Sales (K Pcs), 2017-2022

Table 15. By Type - Global Granulomatosis with Polyangiitis Drug Sales (K Pcs), 2023-2028

Table 16. By Application – Global Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2021 & 2028

Table 17. By Application - Global Granulomatosis with Polyangiitis Drug Revenue (US\$, Mn), 2017-2022

Table 18. By Application - Global Granulomatosis with Polyangiitis Drug Revenue (US\$, Mn), 2023-2028

Table 19. By Application - Global Granulomatosis with Polyangiitis Drug Sales (K Pcs),

2017-2022

Table 20. By Application - Global Granulomatosis with Polyangiitis Drug Sales (K Pcs), 2023-2028

Table 21. By Region – Global Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Granulomatosis with Polyangiitis Drug Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Granulomatosis with Polyangiitis Drug Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Granulomatosis with Polyangiitis Drug Sales (K Pcs), 2017-2022

Table 25. By Region - Global Granulomatosis with Polyangiitis Drug Sales (K Pcs), 2023-2028

Table 26. By Country - North America Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2017-2022

Table 29. By Country - North America Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2023-2028

Table 30. By Country - Europe Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2017-2022

Table 33. By Country - Europe Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2023-2028

Table 34. By Region - Asia Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2017-2022

Table 37. By Region - Asia Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2023-2028

Table 38. By Country - South America Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2017-2022

Table 41. By Country - South America Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2023-2028

Table 42. By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2017-2022

Table 45. By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Sales, (K Pcs), 2023-2028

Table 46. Bionovis SA Corporate Summary

Table 47. Bionovis SA Granulomatosis with Polyangiitis Drug Product Offerings

Table 48. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 49. Bristol-Myers Squibb Company Corporate Summary

Table 50. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Offerings

Table 51. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 52. ChemoCentryx Inc Corporate Summary

Table 53. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Offerings

Table 54. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 55. Coherus BioSciences Inc Corporate Summary

Table 56. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Offerings

Table 57. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 58. Genor BioPharma Co Ltd Corporate Summary

Table 59. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Offerings

Table 60. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 61. GlaxoSmithKline Plc Corporate Summary

Table 62. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Offerings

Table 63. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 64. Iltooo Pharma Corporate Summary

Table 65. Iltooo Pharma Granulomatosis with Polyangiitis Drug Product Offerings

Table 66. Iltooo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 67. Panacea Biotec Ltd Corporate Summary

Table 68. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Offerings

Table 69. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 70. Sandoz International GmbH Corporate Summary

Table 71. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Offerings

Table 72. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 73. The International Biotechnology Center (IBC) Generium Corporate Summary

Table 74. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Offerings

Table 75. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 76. Granulomatosis with Polyangiitis Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)

Table 77. Global Granulomatosis with Polyangiitis Drug Capacity Market Share of Key Manufacturers, 2020-2022

Table 78. Global Granulomatosis with Polyangiitis Drug Production by Region, 2017-2022 (K Pcs)

Table 79. Global Granulomatosis with Polyangiitis Drug Production by Region, 2023-2028 (K Pcs)

Table 80. Granulomatosis with Polyangiitis Drug Market Opportunities & Trends in Global Market

Table 81. Granulomatosis with Polyangiitis Drug Market Drivers in Global Market

Table 82. Granulomatosis with Polyangiitis Drug Market Restraints in Global Market

Table 83. Granulomatosis with Polyangiitis Drug Raw Materials

Table 84. Granulomatosis with Polyangiitis Drug Raw Materials Suppliers in Global Market

Table 85. Typical Granulomatosis with Polyangiitis Drug Downstream

Table 86. Granulomatosis with Polyangiitis Drug Downstream Clients in Global Market

Table 87. Granulomatosis with Polyangiitis Drug Distributors and Sales Agents in Global

Market

List Of Figures

LIST OF FIGURES

Figure 1. Granulomatosis with Polyangiitis Drug Segment by Type

Figure 2. Granulomatosis with Polyangiitis Drug Segment by Application

Figure 3. Global Granulomatosis with Polyangiitis Drug Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Granulomatosis with Polyangiitis Drug Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Granulomatosis with Polyangiitis Drug Revenue, 2017-2028 (US\$, Mn)

Figure 7. Granulomatosis with Polyangiitis Drug Sales in Global Market: 2017-2028 (K Pcs)

Figure 8. The Top 3 and 5 Players Market Share by Granulomatosis with Polyangiitis Drug Revenue in 2021

Figure 9. By Type - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

Figure 10. By Type - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

Figure 11. By Type - Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs), 2017-2028

Figure 12. By Application - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

Figure 13. By Application - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

Figure 14. By Application - Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs), 2017-2028

Figure 15. By Region - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

Figure 16. By Region - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

Figure 17. By Country - North America Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

Figure 18. By Country - North America Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

Figure 19. US Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 20. Canada Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 21. Mexico Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn),

2017-2028

Figure 22. By Country - Europe Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

Figure 24. Germany Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 25. France Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

Figure 33. China Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 37. India Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Granulomatosis with Polyangiitis Drug Revenue Market Share, 2017-2028

Figure 39. By Country - South America Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

Figure 40. Brazil Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug

Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share, 2017-2028

Figure 44. Turkey Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Granulomatosis with Polyangiitis Drug Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Granulomatosis with Polyangiitis Drug Production Capacity (K Pcs), 2017-2028

Figure 49. The Percentage of Production Granulomatosis with Polyangiitis Drug by Region, 2021 VS 2028

Figure 50. Granulomatosis with Polyangiitis Drug Industry Value Chain

Figure 51. Marketing Channels

I would like to order

Product name: Granulomatosis with Polyangiitis Drug Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/GC04C791AFE0EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC04C791AFE0EN.html>